cyproterone and Growth-Disorders

Topics: Adolescent; Adrenal Hyperplasia, Congenital; Age Determination by Skeleton; Androgens; Child; Child Development; Child, Preschool; Chlormadinone Acetate; Choriocarcinoma; Chorionic Gonadotropin; Corpus Luteum Hormones; Cyproterone; Estradiol; Estrogens; Female; Follicle Stimulating Hormone; Gonadotropins, Pituitary; Growth Disorders; Hormones, Ectopic; Humans; Hypothyroidism; Luteinizing Hormone; Pregnancy; Pseudohypoparathyroidism; Puberty, Precocious; Sertoli Cell Tumor; Sex Factors; Testosterone

To evaluate the effect of cyproterone acetate (CA) on the renin-angiotensin-aldosterone axis, we measured the plasma active, inactive and total renin concentrations (PARC, PIRC and PTRC) during and after CA treatment in patients with precocious puberty and genetic short stature. CA was administered at a daily dose of 150-170 mg/m2 in all subjects. PARC and PTRC were measured by immunoradiometric assays. During CA treatment, PARC, PIRC, PTRC and the PARC/PTRC ratio were significantly decreased. The plasma renin activity, measured by enzymatic assay, and the plasma aldosterone concentration were also decreased. After CA discontinuation, all of these were increased immediately along normal ranges. PARC closely correlated with plasma renin activity. These results suggest that CA produces mineralocorticoid action and suppresses the production and activation of renin.

Topics: Androgen Antagonists; Child; Cyproterone; Cyproterone Acetate; Enzyme Precursors; Female; Growth Disorders; Humans; Puberty, Precocious; Renin; Renin-Angiotensin System

125 boys with idiopathic GH deficiency who received GH treatment were followed until they reached their final height. In 85 patients who had spontaneous puberty (group I), the mean final height was 151.5 +/- 6.6 cm. In 23 patients with combined GH and gonadotropin deficiency (group II) whose pubertal development was induced artificially at age 19.4 +/- 2.1 years, the mean final height was 163.7 +/- 3.9 cm (p less than 0.01 vs. group I). Final height was strongly related to height at the onset of pubertal development in combined groups I and II when the time of gonadal replacement treatment was taken as the onset of pubertal development in group II. In 17 patients (group III) who developed spontaneous puberty, gonadal suppression treatment was started at their early stage of puberty and was continued for a mean duration of 4.3 +/- 1.1 years. The mean final height in group III was 157.9 +/- 3.0 cm (p less than 0.01 vs. group I, group II). Longitudinal growth pattern analysis demonstrated that this beneficial effect on final height by gonadal suppression treatment was attributed to the elongation of pubertal growth spurt and pubertal height gain.

Topics: Adolescent; Age Factors; Analysis of Variance; Androgen Antagonists; Body Height; Child; Cyproterone; Cyproterone Acetate; Growth; Growth Disorders; Growth Hormone; Humans; Male; Medroxyprogesterone; Medroxyprogesterone Acetate; Puberty

The most important therapeutic problems of female puberty and adolescence are discussed, including high stature, amenorrhoea, oligomenorrhea, pubertas tarda, anovulation, anorexia, anisomastia, hypermastia. Indications for treatment are given and the possibilities for a prophylactic medicine in this age group are stressed.

Topics: Acne Vulgaris; Adolescent; Amenorrhea; Anorexia Nervosa; Breast Diseases; Child; Cyproterone; Drug Combinations; Endocrine System Diseases; Estradiol Congeners; Ethinyl Estradiol; Female; Growth Disorders; Hirsutism; Humans; Menstruation Disturbances; Obesity; Oligomenorrhea; Progesterone Congeners; Puberty, Precocious

Topics: Age Determination by Skeleton; Androgen Antagonists; Body Height; Bone Development; Child; Child, Preschool; Cyproterone; Growth Disorders; Growth Hormone; Hamartoma; Humans; Hypopituitarism; Male; Pregnadienes; Prognosis; Puberty, Precocious; Skull Neoplasms

Topics: 17-Ketosteroids; Age Determination by Skeleton; Androgen Antagonists; Body Height; Bone Development; Child; Child, Preschool; Cyproterone; Estrogens; Female; Gonadotropins; Growth Disorders; Humans; Male; Pregnadienes; Prognosis; Puberty, Precocious